Cullinan Oncology, Inc.

NASDAQ:CGEM

10.3 (USD) • At close February 5, 2025
Bedrijfsnaam Cullinan Oncology, Inc.
Symbool CGEM
Munteenheid USD
Prijs 10.3
Beurswaarde 599,744,280
Dividendpercentage 0%
52-weken bereik 9.501 - 30.189
Industrie Biotechnology
Sector Healthcare
CEO Mr. Nadim Ahmed
Website https://www.cullinanoncology.com

An error occurred while fetching data.

Over Cullinan Oncology, Inc.

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients

Vergelijkbare Aandelen

Inhibrx, Inc. logo

Inhibrx, Inc.

INBX

13.56 USD

Intercept Pharmaceuticals, Inc. logo

Intercept Pharmaceuticals, Inc.

ICPT

19 USD

Nano-X Imaging Ltd. logo

Nano-X Imaging Ltd.

NNOX

7.28 USD

ANI Pharmaceuticals, Inc. logo

ANI Pharmaceuticals, Inc.

ANIP

59.81 USD

Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc.

CRBU

1.46 USD

Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSC

0.796 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)